Rate Video

iwCLL 2019 | Evaluating acalabrutinib in CLL treatment

Jennifer Woyach • 22 Sep 2019

Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Chlorambucil Obinutuzumab

Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, evaluates the use of acalabrutinib in chronic lymphocytic leukemia (CLL) treatment, in comparison to other therapies. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

The future of CLL treatment: more selective and reversible BTK inhibitors

Jennifer Woyach • 21 Oct 2020

MRD in CLL: in which settings is its use most important?

Jennifer Woyach • 7 Dec 2019

Promises and challenges in up-and-coming CLL therapies

Jennifer Woyach • 16 Apr 2018

Key BTK inhibitor trials for the initial treatment of CLL

Jennifer Woyach • 20 Oct 2020

Related Videos

Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain • 17 Feb 2021

SIERRA trial updates: apamistamab in AML

Tania Jain • 12 Feb 2021

CAR-T vs. BiTEs in B-cell malignancies

Marion Subklewe • 11 Feb 2021

Flotetuzumab as salvage therapy for primary induction failure and early AML

Ibrahim Aldoss • 11 Feb 2021